Literature DB >> 11160264

Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination.

R Tisch1, B Wang, D J Weaver, B Liu, T Bui, J Arthos, D V Serreze.   

Abstract

In this study, we have investigated the use of plasmid DNA (pDNA) vaccination to elicit Th2 effector cell function in an Ag-specific manner and in turn prevent insulin-dependent diabetes mellitus (IDDM) in nonobese diabetic (NOD) mice. pDNA recombinants were engineered encoding a secreted fusion protein consisting of a fragment of glutamic acid decarboxylase 65 (GAD65) linked to IgGFc, and IL-4. Intramuscular injection of pDNA encoding GAD65-IgGFc and IL-4 effectively prevented diabetes in NOD mice treated at early or late preclinical stages of IDDM. This protection was GAD65-specific since NOD mice immunized with pDNA encoding hen egg lysozyme-IgGFc and IL-4 continued to develop diabetes. Furthermore, disease prevention correlated with suppression of insulitis and induction of GAD65-specific regulatory Th2 cells. Importantly, GAD65-specific immune deviation was dependent on pDNA-encoded IL-4. In fact, GAD65-specific Th1 cell reactivity was significantly enhanced in animals immunized with pDNA encoding only GAD65-IgGFc. Finally, NOD.IL4(null) mice treated with pDNA encoding GAD65-IgGFc and IL-4 continued to develop diabetes, indicating that endogenous IL-4 was also required for disease prevention. These results demonstrate that pDNA vaccination is an effective strategy to elicit beta cell-specific Th2 regulatory cell function for the purpose of preventing IDDM even at a late stage of disease development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160264     DOI: 10.4049/jimmunol.166.3.2122

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats.

Authors:  Peter Celec; Július Hodosy; Roman Gardlík; Michal Behuliak; Roland Pálffy; Marek Pribula; Peter Jáni; Ján Turňa; Katarína Sebeková
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice.

Authors:  A Gauvrit; M Debailleul; A-T Vu; P Sai; J-M Bach
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 3.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

Review 4.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

5.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes.

Authors:  J S Petersen; S Bregenholt; V Apostolopolous; D Homann; T Wolfe; A Hughes; K De Jongh; M Wang; T Dyrberg; M G Von Herrath
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 8.  Clinical potential of antigen-specific therapies in type 1 diabetes.

Authors:  Ken T Coppieters; Birgit Sehested Hansen; Matthias G von Herrath
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 9.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.